In a clinical study published today in PLOS ONE, the UBC team, led by Prof. Patrick McGeer, applied aurin tricarboxylic acid (ATA), a non-toxic drug, to blood samples of five patients with PNH who were undergoing standard treatment with antibodies administered through biweekly infusions.
The researchers found the addition of ATA restored blood cell resistance to complement system attacks, while the antibodies alone did not offer full protection.
Treatment discovered for rare blood cancer
Source: Science Daily
Image credits: Mahidol university
Follow Art and Science of Laboratory Medicine on